(MENAFN- GlobeNewsWire - Nasdaq) Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets's offering.
Market Overview
A recent comprehensive study analyses the global achondroplasia market's current scenario and future growth prospects, shedding light on emerging therapies and the projected market landscape through 2032. Achondroplasia, a major genetic bone disorder that often results in dwarfism, has seen advancements in diagnostic methods and treatment modalities.
Diagnostic Enhancements and Treatment Advances
The diagnosed prevalence of achondroplasia is on the rise in the US, thanks to enhanced genetic testing and growing awareness among medical professionals. The only treatment currently approved in the US and Europe is VOXZOGO (vosoritide), a C-type natriuretic peptide analog, while Japan also recognizes growth hormone therapy. Despite controversies over long-term benefits, these treatments represent a significant step forward in the multidisciplinary management of achondroplasia.
Call for More Efficacious Therapies
With the lack of curative treatment for achondroplasia, there is an urgent need for more effective therapies to not only manage but also improve the complications and quality of life among patients. The pipeline for achondroplasia includes potential therapies that could change the game in symptom alleviation and condition management.
Economic Impact and Forecast
The market report discusses the economic burdens, quality of life impacts, and the comprehensive epidemiology forecast for seven major markets, which includes the United States, EU4, the United Kingdom, and Japan. The US is currently leading the achondroplasia market revenue and is expected to see continuous growth by 2032.
The Promise of Emerging Therapies
Looking ahead, the market is set to evolve with the anticipated approval of emerging therapies. These promising treatments have the potential to alter the current treatment landscape and introduce new options in managing this genetic condition.
Report Insight
This study is a guiding resource that provides detailed market insights, epidemiology, and a forecasted market landscape for achondroplasia, offering strategic insights into current treatments, unmet needs, and forthcoming developments. With a methodical analysis of the 7MM through 2032, healthcare stakeholders can gauge the evolving dynamics and therapeutic offerings within the achondroplasia market space.
A selection of companies mentioned in this report includes, but is not limited to
Ascendis Pharma QED Therapeutics (BridgeBio) Novartis Sanofi RIBOMIC
Key Topics Covered
Key Insights
Report Introduction
Achondroplasia Market Overview at a Glance
Methodology of Achondroplasia Epidemiology and Market
Executive Summary of Achondroplasia
Key Events
Disease Background and Overview
Patient Journey
Epidemiology and Patient Population
Marketed Drugs
Emerging Drugs
Achondroplasia: Market Analysis
Key Opinion Leaders' Views
SWOT Analysis
Unmet Needs
Market Access and Reimbursement
Appendix
Publisher Capabilities
Disclaimer
For more information about this report visit
About ResearchAndMarkets
ResearchAndMarkets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
MENAFN08042024004107003653ID1108069977
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.